Retatrutide has attracted significant attention because early clinical research produced substantial changes in body weight. Understanding those results requires looking at how the trial was designed, who participated, what researchers measured, and what the study could not establish. The pivotal Phase 2 study was a randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine. It evaluated retatrutide in 338 adults with obesity or overwe